Evaluating the impact of the Orphan Drug Act's seven-year market exclusivity period

Health Affairs

Volumn 37, Issue 5, 2018, Pages 732-737

  Sarpatwari, Ameet ^a   Beall, Reed F ^a   Abdurrob, Abdurrahman ^a   He, Mengdong ^a   Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NEW DRUG; ORPHAN DRUG;

ACT; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DRUG APPROVAL; DRUG INDICATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SCREENING; ECONOMIC ASPECT; EXPIRATION DATE; FOOD AND DRUG ADMINISTRATION; MOLECULE; ORPHAN DRUG ACT; PATENT; RARE DISEASE; RETROSPECTIVE STUDY; THERAPEUTIC EQUIVALENCE; DRUG INDUSTRY; EVALUATION STUDY; FEMALE; HUMAN; LEGISLATION AND JURISPRUDENCE; MALE; MARKETING; QUALITY CONTROL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; UNITED STATES;

COHORT STUDIES; DRUG APPROVAL; DRUG INDUSTRY; FEMALE; HUMANS; MALE; MARKETING; ORPHAN DRUG PRODUCTION; QUALITY CONTROL; RARE DISEASES; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85046795968     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2017.1179     Document Type: Article

References (31)

1. Food and Drug Administration. Funding for rare diseases and pediatric device consortia [Internet]. Silver Spring (MD): FDA; [last updated 2017 Dec 18; cited 2018 Feb 26]. Available from: https://www .fda.gov/ScienceResearch/Funding forRareDiseases
2. Haffner ME. History of orphan drug regulation-United States and beyond. Clin Pharmacol Ther. 2016; 100(4):342-3
3. Kesselheim AS. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. Milbank Q. 2011;89(3):450-502
4. Goldman DP, Lakdawalla DN, Malkin JD, Romley J, Philipson T. The benefits from giving makers of conventional "small molecule" drugs longer exclusivity over clinical trial data. Health Aff (Millwood). 2011; 30(1):84-90
5. US Senate [Internet]. Washington (DC): US Senate; 2017. Press release, Hatch introduces bill to incentivize development of treatment for rare diseases; 2017 Jul 3 [cited 2018 Feb 26]. Available from: https://www .hatch.senate.gov/public/index .cfm/releases?ID=18829FAB-B953-4EEE-BE38-976C89F60B70
6. Engelberg AB, KesselheimAS, Avorn J. Balancing innovation, access, and profits-market exclusivity for biologics. N Engl J Med. 2009;361(20): 1917-9
7. Luo J, Kesselheim AS. The Trans-Pacific Partnership agreement and implications for access to essential medicines. JAMA. 2015;314(15): 1563-4
8. Hemphill CS, Sampat BN. Evergreening, patent challenges, and effective market life in pharmaceuticals. J Health Econ. 2012;31(2):327-39
9. Kapczynski A, Park C, Sampat B. Polymorphs and prodrugs and salts (oh my!): an empirical analysis of "secondary" pharmaceutical patents. PLoS One. 2012;7(12):e49470
10. Gupta R, Kesselheim AS, Downing N, Greene J, Ross JS. Generic drug approvals since the 1984 Hatch-Waxman Act. JAMA Intern Med. 2016;176(9):1391-3
11. Rai A. Use patents, carve-outs, and incentives-a new battle in the drugpatent wars. N Engl J Med. 2012; 367(6):491-3
12. Hemphill CS, Sampat B. Intellectual property. Drug patents at the Supreme Court. Science. 2013; 339(6126):1386-7
13. Sarpatwari A, Avorn J, Kesselheim AS. Progress and hurdles for followon biologics. N Engl J Med. 2015; 372(25):2380-2
14. Lanjouw JO. Patents, price controls and access to new drugs: how policy affects global market entry [Internet]. Cambridge (MA): National Bureau of Economic Research; 2005 May [cited 2018 Feb 26]. (NBER Working Paper No. 11321). Available from: http://www.nber.org/papers/ w11321.pdf
15. To access the appendix, click on the Details tab of the article online
16. Environmental Protection Agency. R.E.D. facts: capsaicin [Internet]. Washington (DC): EPA; 1992 Jun [cited 2018 Feb 26]. Available from: https://archive.epa.gov/pesticides/ reregistration/web/pdf/4018fact .pdf
17. Food and Drug Administration. Highlights of prescribing information: Somatuline® Depot (lanreotide) injection [Internet]. Silver Spring (MD): FDA; [revised 2014 Dec; cited 2018 Feb 26]. Available from: https://www.accessdata.fda .gov/drugsatfda_docs/label/2014/ 022074s011lbl.pdf
18. Government Accountability Office. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance [Internet]. Washington (DC): GAO; 2017 Jan [cited 2018 Feb 26]. Available from: http://www.gao .gov/assets/690/682391.pdf
19. Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007; 297(5):480-8
20. Kesselheim AS, Rome BN, Sarpatwari A, Avorn J. Six-month market exclusivity extensions to promote research offer substantial returns for many drug makers. Health Aff (Millwood). 2017; 36(2):362-70
21. European Parliament. Regulation (EC) No. 141/2000 [Internet]. Brussels: European Commission; 1999 [cited 2018 Feb 26]. Available from: https://ec.europa.eu/health/ sites/health/files/files/eudralex/ vol-1/reg_2000_141_cons-2009-07/ reg_2000_141_cons-2009-07_en .pdf
22. Tribble SJ, Lupkin S. Drugs for rare diseases have become uncommonly rich monopolies. National Public Radio [serial on the Internet]. 2017 Jan 17 [cited 2018 Feb 26]. Available from: https://www.npr.org/ sections/health-shots/2017/01/17/ 509506836/drugs-for-rare-diseaseshave-become-uncommonly-richmonopolies
23. EvaluatePharma. Orphan drug report 2015 [Internet]. London: EvaluatePharma; 2015 Oct [cited 2018 Feb 26]. Available from: http:// info.evaluategroup.com/rs/607-YGS-364/images/EPOD15.pdf
24. Tribble SJ, Lupkin S. Sky-high prices for orphan drugs slam American families and insurers. Kaiser Health News [serial on the Internet]. 2017 Jan 17 [cited 2018 Feb 26]. Available from: http://khn.org/ news/sky-high-prices-for-orphandrugs-slam-american-families-andinsurers/
25. Ernst and Young. Impact of the orphan drug tax credit on treatments for rare disease [Internet]. London: Ernst and Young; 2015 Jun [cited 2018 Feb 26]. Available from: https://rarediseases.org/assets/ files/white-papers/2015-06-17.nordbio-ey-odtc.pdf
26. Graham J. Biotechs push to save tax credit for rare-disease medicine makers. Boston Herald [serial on the Internet]. 2013 Aug 11 [cited 2018 Feb 27]. Available from: http:// www.bostonherald.com/business/ healthcare/2013/08/biotechs_ push_to_save_tax_credit_for_ rare_disease_medicine_makers# sthash.boVn5v9O.dpuf
27. Kesselheim AS, Treasure CL, Joffe S. Biomarker-defined subsets of common diseases: policy and economic implications of Orphan Drug Act coverage. PLoS Med. 2017;14(1): e1002190
28. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. Report to Congress: prescription drugs: innovation, spending, and patient access [Internet]. Washington (DC): ASPE; 2016 Dec 7 [cited 2018 Feb 26]. Available from: https://delauro.house.gov/ sites/delauro.house.gov/files/ Prescription-Drugs-Innovation-Spending-and-Patient-Access-12-07-16.pdf
29. Dennis B. FDA's "safe and effective" drug approval based on widely varied data, study finds. Washington Post. 2014 Jan 21
30. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011;305(22):2320-6
31. Dave CV, Kesselheim AS, Fox ER, Qiu P, Hartzema A. High generic drug prices and market competition: a retrospective cohort study. Ann Intern Med. 2017;167(3):145-51